New drug targets stomach and pancreatic cancers in early trial

NCT ID NCT07460375

Recruiting now Disease control Sponsor: LigaChem Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safest dose, then expanding to see how well it works in certain tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

ASAN Medical Center
NOT_YET_RECRUITING

Seoul, 05505, South Korea
MD Anderson Cancer Center
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Mass General Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02214, United States
Medical University of South Carolina
NOT_YET_RECRUITING

Charleston, South Carolina, 29406, United States
Princess Margaret Hospital
NOT_YET_RECRUITING

Toronto, Ontario, M5S 3H2, Canada
START New York - Long Island
RECRUITING

Lake Success, New York, 11042, United States
Samsung Medical Center
NOT_YET_RECRUITING

Seoul, 06351, South Korea
Seoul National University Hospital
NOT_YET_RECRUITING

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.